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A commentary on
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response to mitogens. I. The responding
cell
by Gery I, Gershon RK, Waksman BH.
J Exp Med (1972) 136(1):128–42. doi:
10.1084/jem.136.1.128
Potentiation of the T-lymphocyte response
to mitogens. II. The cellular source of
potentiating mediator(s)
by Gery I, Waksman BH. J Exp Med (1972)
136(1):143–55. doi: 10.1084/jem.136.1.143
The idea that soluble cell products play
important roles in the complex process of
the immune response was supported by
scientific evidence in the sixties in sev-
eral publications including those by David
et al. (1) and Bloom and Bennett (2),
who discovered the activity of macrophage
migration inhibitory factor (MIF), Gor-
don and McLean (3) who reported that
media of leukocyte cultures contain mito-
genic factors, Kasakura and Lowenstein
(4), who showed the activity of a “blas-
togenic factor” and Ruddle and Waksman
(5), who discovered the activity of lym-
photoxin. Further, a 1970 paper by Bach
et al. (6) reported on a soluble factor
that could replace macrophages in purified
lymphocyte proliferative responses.
Unlike the factors mentioned above, the
definition of lymphocyte activating fac-
tor (LAF) was a result of a study aimed
at an entirely different purpose. In May
1970, I came to the lab of Byron Waks-
man, at Yale University, for a sabbatical
from my position at the Hebrew Uni-
versity Medical School. Prior to coming
to Yale I acquired expertise in culturing
lymphocytes and Richard (Dick) Gershon,
who collaborated with Waksman’s group,
approached me with the idea to use this
expertise for studying the activity of the
“suppressor cells” he discovered. It is of
note that the concept of a population of
lymphocytes whose function is suppres-
sion of immune responses by other lym-
phocyte populations was revolutionary at
that time and Dick had to struggle to get
his data published; his seminal paper on
suppressor cells was finally accepted by
Immunology (7). The experiment Dick sug-
gested was to inject naïve mice with large
(“tolerizing”) doses of sheep red blood
cells (RBC) and to test lymphocytes from
these treated mice for their proliferative
responses in culture to the mitogen phy-
tohemagglutinin (PHA) in the presence of
sheep RBC. We focused on spleen lympho-
cytes of the treated mice, but we also exam-
ined the response of thymus cells of the
injected mice. For specificity controls we
used human whole blood cells (from a col-
league donor). The mouse spleen cultures
exhibited a moderate level of suppressed
response to PHA (8). In addition, however,
I noticed an unexpected response: vigorous
proliferation by thymus cell cultures incu-
bated with human RBC (our control. . .)
and PHA. The thymocytes did not respond,
however, to PHA alone. Further analysis of
the unexpected finding established that this
was not a fluke and revealed that the thy-
mocyte response was actually triggered by
the small number of leukocytes that “con-
taminated” the fresh human RBC prepara-
tion. Indeed, when using purified human
blood leukocytes, as few as 6,000 of these
cells, along with PHA, were sufficient to
stimulate a significant response by the thy-
mocytes. The next step was, obviously, to
examine the supernatant of human leuko-
cytes for stimulatory activity and I was
delighted to find that the supernatant had
strong stimulatory activity on the thymo-
cyte response to PHA. We believed that
these preliminary observations were of suf-
ficient importance and summarized them
as a short communication in the Journal of
Immunology (9).
During the following months of my sab-
batical at Yale I expanded the research,
focusing on two related issues: the analy-
sis of the responding cells and of the cells
that produce the stimulating factor. At that
stage we had to give the factor a name
and we chose “Lymphocyte activating fac-
tor” or “LAF”. The best responding cells
were identified to be the more mature
thymocytes, but LAF also stimulated the
response of less mature thymocytes, as well
as the response to stimulants by murine
spleen cells. Useful information was par-
ticularly provided by the analysis of the
LAF producing cells and their stimulants.
High levels of LAF activity were secreted by
adherent cells (mostly macrophages) stim-
ulated by lipopolysaccharide (LPS) and
by non-adherent lymphocytes stimulated
with PHA or concanavalin A. In hindsight,
it seems that the macrophages produced
LAF activity, whereas the PHA-stimulated
lymphocytes released mainly another stim-
ulatory factor. It is also noteworthy that the
LPS used in these preliminary experiments
was a gift from the lab of Elisha Atkins,
two floors below our lab. Elisha and his
group had been using LPS as a stimulant
for the production of the endogenous pyro-
genic factor they measured by inducing
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fever in animals. That batch of LPS was also
used in a study we carried out at the same
time showing for the first time that LPS is
mitogenic for B-cells (10).
Before leaving New Haven I left with
Byron Waksman drafts for two manu-
scripts that summarized the data. Byron
rewrote the manuscripts that were accepted
for publication by the Journal of Experi-
mental Medicine. The first paper (11) is
co-authored by Byron Waksman and Dick
Gershon, but Dick was not included in the
authors’ list of the second one (12). This
was clearly unfair to Dick and I certainly
feel badly about it.
During my last months in New Haven
I also contacted Bob Handschumacher, at
the Department of Pharmacology atYale, to
help me with the characterization of LAF.
We carried out some preliminary experi-
ments, but in order to complete the study
I returned to New Haven in the summer
of 1972 and together with Bob we col-
lected some basic information on the fac-
tor, including the finding that LAF is a
protein, with a size of ~15 kDa. We sub-
mitted a manuscript that summarized the
data to the Journal of Immunology, but the
manuscript was rejected. We then submit-
ted it to Cellular Immunology (13) and
were delighted to learn that this paper was
subsequently highly cited.
Later studies by other groups [e.g., Ref.
(14)] revealed that highly purified “LAF”
preparations functioned to promote the
production of a T cell-derived activity,
which was the basis for the interleukin
nomenclature, first proposed at the Sec-
ond International Lymphokine Workshop
in 1979 at Ermatigen Switzerland.
Thus, “interleukin-1 (IL-1)” made by
macrophages was distinguishable from
“IL-2”, made by lymphocytes (14).
Looking back, I feel lucky for includ-
ing the human “RBC” control cultures in
the initial experiment performed 44 years
ago and proud for pursuing the unex-
pected and weird result by the subsequent
experiments that yielded the definition of
the LAF.
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